Display options
Cite
Querol-Vilaseca M, Sirisi S, Molina-Porcel L, et al. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. Neuropathol Appl Neurobiol. 2021;doi: 10.1111/nan.12781.
Querol-Vilaseca, M., Sirisi, S., Molina-Porcel, L., Molina, B., Pegueroles, J., Ferrer-Raventós, P., Nuñez-Llaves, R., Dols-Icardo, O., Balasa, M., Iulita, M. F., Blesa, R., Belbin, O., Clarimon, J., Fortea, J., Gelpi, E., Sánchez-Valle, R., & Lleó, A. (2021). Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. Neuropathology and applied neurobiology, . https://doi.org/10.1111/nan.12781
Querol-Vilaseca, Marta, et al. "Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat." Neuropathology and applied neurobiology vol. (2021). doi: https://doi.org/10.1111/nan.12781
Querol-Vilaseca M, Sirisi S, Molina-Porcel L, Molina B, Pegueroles J, Ferrer-Raventós P, Nuñez-Llaves R, Dols-Icardo O, Balasa M, Iulita MF, Blesa R, Belbin O, Clarimon J, Fortea J, Gelpi E, Sánchez-Valle R, Lleó A. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. Neuropathol Appl Neurobiol. 2021 Nov 25; doi: 10.1111/nan.12781. Epub 2021 Nov 25. PMID: 34825396.
Copy Download .nbib Format: NLM
Share it on

Neuropathol Appl Neurobiol. 2021 Nov 25; doi: 10.1111/nan.12781. Epub 2021 Nov 25.

Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.

Neuropathology and applied neurobiology

Marta Querol-Vilaseca, Sònia Sirisi, Laura Molina-Porcel, Beatriu Molina, Jordi Pegueroles, Paula Ferrer-Raventós, Raúl Nuñez-Llaves, Oriol Dols-Icardo, Mircea Balasa, Maria Florencia Iulita, Rafael Blesa, Olivia Belbin, Jordi Clarimon, Juan Fortea, Ellen Gelpi, Raquel Sánchez-Valle, Alberto Lleó

Affiliations

  1. Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  2. Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  3. Neurological Tissue Bank of the Biobanc-Hospital Clínic-IDIBAPS, Barcelona, Spain.
  4. Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain.
  5. Institute of Neurology, Medical University of Vienna, Vienna, Austria.

PMID: 34825396 DOI: 10.1111/nan.12781

Abstract

We report the neuropathological examination of a patient with Alzheimer's disease (AD) treated for 38 months with low doses of the BACE-1 inhibitor verubecestat. Brain examination showed small plaque size, reduced dystrophic neurites around plaques and reduced synaptic-associated Aβ compared with a group of age-matched untreated sporadic AD (SAD) cases. Our findings suggest that BACE-1 inhibition has an impact on synaptic soluble Aβ accumulation and neuritic derangement in AD.

© 2021 British Neuropathological Society.

Keywords: Alzheimer's disease; BACE-1; amyloid beta; amyloid plaques; synapse; verubecestat

References

  1. Das B, Yan R. A close look at BACE1 inhibitors for Alzheimer's disease treatment. CNS Drugs [Internet]. 2019;33(3):251-263. https://doi.org/10.1007/s40263-019-00613-7 - PubMed
  2. Scott JD, Li SW, Brunskill APJ, et al. Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-8931)-a β-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer's disease. J Med Chem. 2016;59(23):10435-10450. - PubMed
  3. Lovestone S, Boada M, Dubois B, et al. A phase II trial of tideglusib in Alzheimer's disease. J Alzheimers Dis. 2015;45(1):75-88. - PubMed
  4. Egan MF, Kost J, Tariot PN, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. N Engl J Med. 2018;378(18):1691-1703. - PubMed
  5. Lee EB, Leng LZ, Zhang B, et al. Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J Biol Chem. 2006;281(7):4292-4299. - PubMed
  6. Monsell SE, Kukull WA, Roher AE, et al. Characterizing apolipoprotein E ε4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal β-amyloid peptide plaques. JAMA Neurol. 2015;72(10):1124-1131. - PubMed
  7. Gomez-Arboledas A, Davila JC, Sanchez-Mejias E, et al. Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease. Glia. 2018;66(3):637-653. - PubMed
  8. Hadley KC, Rakhit R, Guo H, et al. Determining composition of micron-scale protein deposits in neurodegenerative disease by spatially targeted optical microproteomics. Elife. 2015;4:1-21. - PubMed
  9. Sadleir KR, Kandalepas PC, Buggia-Prévot V, Nicholson DA, Thinakaran G, Vassar R. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease. Acta Neuropathol. 2016;132(2):235-256. - PubMed
  10. Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer's disease. N Engl J Med. 2019;380(15):1408-1420. - PubMed
  11. Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G. Preliminary results of a trial of atabecestat in preclinical Alzheimer's disease. N Engl J Med. 2019;380(15):1483-1485. - PubMed
  12. Peters F, Salihoglu H, Rodrigues E, et al. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology. Acta Neuropathol [Internet]. 2018;135(5):695-710. https://doi.org/10.1007/s00401-017-1804-9 - PubMed
  13. Das B, Yan R. Role of BACE1 in Alzheimer's synaptic function. Transl Neurodegener. 2017;6(1):4-11. - PubMed
  14. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science (80-). 2002;298(5594):789-791. - PubMed
  15. Kandalepaas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA, Vassar R. The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 2013;126(3):329-352. - PubMed

Publication Types

Grant support